OverviewSuggest Edit

BioInvent focuses on the discovery and development of antibody-based drugs against cancer. The Company's lead drug candidate is BI-1206, a human antibody targeting CD32b, an immunosuppressive protein that is expressed in patients with B-cell cancers. The BI-1206 drug is in Phase I/II clinical trials currently ongoing in patients with non-Hodgkin lymphoma and chronic lymphocytic leukaemia who are resistant to rituximab. It is also developing immuno-modulatory antibodies, such as cancer-associated regulatory T cells and tumour-associated myeloid-derived suppressor cells.

TypePublic
Founded1997
HQLund, SE
Websitebioinvent.com

Latest Updates

Employees (est.) (Sept 2020)72(+5%)
Share Price (Sept 2020)KR1.6 (+3%)
Cybersecurity ratingBMore

Key People/Management at BioInvent

Martin Welschof

Martin Welschof

CEO
Kristoffer Rudenholm Hansson

Kristoffer Rudenholm Hansson

Senior Vice President, Technical Operations
Show more

BioInvent Office Locations

BioInvent has an office in Lund
Lund, SE (HQ)
The Gamma Building Sölvegatan 41
Lund, SE
Scheelevägen 17
Show all (2)

BioInvent Financials and Metrics

BioInvent Revenue

Market capitalization (15-Sept-2020)

1.6b

Closing stock price (15-Sept-2020)

1.6
BioInvent's current market capitalization is kr1.6 b.
Show all financial metrics

BioInvent Cybersecurity Score

Cybersecurity ratingPremium dataset

B

85/100

SecurityScorecard logo

BioInvent Online and Social Media Presence

Embed Graph

BioInvent News and Updates

BioInvent Interim Report January 1 - June 30, 2020

LUND, Sweden, Aug. 27, 2020 /PRNewswire/ -- "BioInvent is fully focused on moving our clinical projects forward. Our successful financing of SEK 625 million has strengthened our institutional investor base and is truly transformative for the company as it allows us to broaden and develop...

BioInvent to Host Key Opinion Leader Call on Enhancing Checkpoint Inhibitors for the Treatment of Solid Cancers

LUND, Sweden, July 13, 2020 /PRNewswire/ -- Call & Webcast on Tuesday, July 21 at 10 a.m. Eastern Time BioInvent International AB ("BioInvent" or the "Company") (OMXS: BINV) ), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory...

BioInvent Extends Research Collaboration and License Agreement With Pfizer Inc.

LUND, Sweden, July 1, 2020 /PRNewswire/ -- BioInvent International AB ("BioInvent" or the "Company") (OMXS: BINV) today announces that it has further extended the research term under its cancer immunotherapy research collaboration and license agreement with Pfizer Inc. ("Pfizer") until...

BioInvent Submits a CTA for a Phase I/IIa trial of BI-1808, A First-in-class Anti-TNFR2 Antibody for the Treatment of Patients With Solid Tumors and CTCL

LUND, Sweden, June 30, 2020 /PRNewswire/ -- BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces it has submitted a clinical...

BioInvent Enrolls First Patient in Phase I/IIa Trial of BI-1206 in Combination With KEYTRUDA® for the Treatment of Patients With Solid Tumors

LUND, Sweden, June 23, 2020 /PRNewswire/ -- BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces the enrollment of the first...

BioInvent Presents Proof-of-concept Data for two TNFR2-targeting Antibodies

LUND, Sweden, June 22, 2020 /PRNewswire/ -- BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today presents new proof-of-concept data for two...
Show more

BioInvent Frequently Asked Questions

  • When was BioInvent founded?

    BioInvent was founded in 1997.

  • Who are BioInvent key executives?

    BioInvent's key executives are Martin Welschof and Kristoffer Rudenholm Hansson.

  • How many employees does BioInvent have?

    BioInvent has 72 employees.

  • Who are BioInvent competitors?

    Competitors of BioInvent include Cellectar Biosciences, A&G Pharmaceutical and Isotopen Technologien Munchen.

  • Where is BioInvent headquarters?

    BioInvent headquarters is located at The Gamma Building Sölvegatan 41, Lund.

  • Where are BioInvent offices?

    BioInvent has an office in Lund.

  • How many offices does BioInvent have?

    BioInvent has 2 offices.